Drew Ranieri
Stock Analyst at Morgan Stanley
(1.24)
# 3,749
Out of 5,140 analysts
170
Total ratings
45.65%
Success rate
-11.39%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SIBN SI-BONE | Maintains: Overweight | $20 → $23 | $16.98 | +35.45% | 16 | Dec 2, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $70 → $100 | $94.15 | +6.21% | 14 | Dec 2, 2025 | |
| ATEC Alphatec Holdings | Maintains: Equal-Weight | $16 → $21 | $17.03 | +23.31% | 11 | Nov 10, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $3.84 | +56.25% | 4 | Mar 5, 2025 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $362.94 | +22.61% | 9 | Dec 2, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $12.19 | +121.49% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $2.61 | +206.51% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $19.44 | +13.17% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $16.93 | -52.75% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $5.20 | +1,486.54% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $24.67 | +54.03% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $70.11 | +36.93% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $12.86 | +102.18% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $206.18 | +43.08% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $102.96 | +171.95% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $8.00 | -37.50% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $19.71 | +255.15% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $523.69 | -42.71% | 6 | Apr 25, 2022 |
SI-BONE
Dec 2, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $16.98
Upside: +35.45%
Globus Medical
Dec 2, 2025
Maintains: Overweight
Price Target: $70 → $100
Current: $94.15
Upside: +6.21%
Alphatec Holdings
Nov 10, 2025
Maintains: Equal-Weight
Price Target: $16 → $21
Current: $17.03
Upside: +23.31%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $3.84
Upside: +56.25%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $362.94
Upside: +22.61%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $12.19
Upside: +121.49%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $2.61
Upside: +206.51%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $19.44
Upside: +13.17%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $16.93
Upside: -52.75%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $5.20
Upside: +1,486.54%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $24.67
Upside: +54.03%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $70.11
Upside: +36.93%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $12.86
Upside: +102.18%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $206.18
Upside: +43.08%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $102.96
Upside: +171.95%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $8.00
Upside: -37.50%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $19.71
Upside: +255.15%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $523.69
Upside: -42.71%